Table 2.
Comparison of baseline characteristics at hemodialysis initiation between patients who subsequently developed central CUA and those who developed peripheral CUA
| Characteristic | Central CUA (n=582) | Peripheral CUA (n=128) | P Value |
|---|---|---|---|
| Demographics | |||
| Age, yr | 53±14 | 56±15 | 0.02 |
| Sex, female % | 73 | 61 | 0.02 |
| Race | 0.26 | ||
| White, % | 57 | 49 | |
| Black, % | 26 | 32 | |
| Other, % | 17 | 19 | |
| Comorbidities and vital signs | |||
| Diabetes mellitus, % | 62 | 55 | 0.15 |
| Obesity, % | 70 | 54 | 0.002 |
| Weight, kg | 103.9±27.1 | 94.7±28.4 | 0.003 |
| BMI, kg/m2 | 37.7±9.9 | 33.8±9.2 | <0.001 |
| Systolic BP, mmHg | 149±30 | 153±35 | 0.29 |
| Diastolic BP, mmHg | 77±17 | 81±23 | 0.08 |
| Mineral bone parameters and therapies | |||
| Serum calcium (albumin corrected), mg/dl | 9.1±0.8 | 9.0±0.8 | 0.47 |
| Serum phosphorus, mg/dl | 4.8±2.2 | 4.8±2.3 | 0.92 |
| Serum PTH, pg/ml | 366 (180, 638) | 403 (219, 659) | 0.96 |
| Serum ALP, U/L | 116.6±83.5 | 123.2±109.4 | 0.54 |
| Serum 25-hydroxyvitamin D, ng/ml | 18.7±11.3 | 20.1±11.2 | 0.25 |
| Dialysate calcium, mmol/L | 2.5±0.3 | 2.5±0.3 | 0.55 |
| Nutritional vitamin D treatment, % | 8 | 8 | 0.96 |
| Activated vitamin D treatment, % | 36 | 43 | 0.14 |
| Cinacalcet treatment, % | 6 | 5 | 0.63 |
| Phosphate-binding agent treatment, % | 37 | 40 | 0.63 |
| Other laboratory parameters and medications | |||
| Serum albumin, g/dl | 3.5±0.6 | 3.6±0.6 | 0.16 |
| Hemoglobin, g/dl | 10.4±1.8 | 10.3±1.6 | 0.65 |
| Serum bicarbonate, mEq/L | 22.0±4.0 | 22.1±4.2 | 0.94 |
| sPKtV | 1.5±0.5 | 1.4±0.4 | 0.51 |
| Warfarin treatment, % | 18 | 8 | 0.01 |
| Statin treatment, % | 26 | 21 | 0.34 |
| Erythropoiesis-stimulating agent treatment, % | 51 | 48 | 0.57 |
| Angiotensin pathway blocker treatment, % | 17 | 14 | 0.38 |
| Insulin treatment, % | 22 | 14 | 0.06 |
Mean ± SD is reported for all continuous variables except for serum PTH where IQR is reported. ALP, alkaline phosphatase; sPKtV, single pool KtV.